[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340226-105":59,"doc-detail-340226-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","seomgetnettcc-clinical-guideline-thyroid-cancer-2023","SEOM‑GETNE‑TTCC Clinical guideline thyroid cancer (2023)","","Thyroid cancer constitutes 3% of global cancer incidence and is a leading endocrine malignancy. Evolving treatment decisions increasingly rely on risk assessment, molecular profiling, and imaging evaluation, enabling targeted agents that change disease trajectory. This guideline provides a comprehensive, practical synthesis of current status and the latest updates in thyroid cancer management. It emphasizes stage-based assessment from initial diagnosis through long-term follow-up to support appropriate care decisions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/seomgetnettcc-clinical-guideline-thyroid-cancer-2023/340226/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/seomgetnettcc-clinical-guideline-thyroid-cancer-2023/340226.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-22","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What key factors are used to optimize thyroid cancer treatment decisions in recent practice?","Question",{"text":112,"@type":113},"Treatment decisions are increasingly optimized using risk assessment, molecular profiling, and imaging assessment, which supports more tailored strategies and targeted agents.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How common is thyroid cancer and what is its mortality share?",{"text":117,"@type":113},"Thyroid cancer accounts for 3% of global cancer incidence and is the most common endocrine malignancy; it represents about 0.5% of mortality with an estimated number of cases reported in the article.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the standard diagnostic process for a patient with a suspicious thyroid nodule?",{"text":121,"@type":113},"The guideline describes blood tests for thyroid function, ultrasound scans, and fine-needle aspiration cytology (FNAC), with ultrasound features and risk levels guiding the need for FNAC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340226,1790165526,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Clinical and Translational Oncology (2024) 26:2902–2916  \n[https://doi.org/10.1007/s12094-024-03736-6](https://doi.org/10.1007/s12094-024-03736-6)  \nSEOM‑GETNE‑TTCC Clinical guideline thyroid cancer (2023)  \nTeresa Alonso‑Gordoa1 · Paula Jimenez‑Fonseca2 · Javier Martinez‑Trufero3 · Miguel Navarro4 · Ignacio Porras5 · Jordi Rubió‑Casadevall6 · Marta Arregui Valles7 · Neus Basté8 · Jorge Hernando9 · Lara Iglesias Docampo10  \nAccepted: 12 September 2024 / Published online: 26 September 2024 © The Author(s) 2024  \nAbstract  \nThyroid cancer (TC) represents 3% of global cancer incidence. Recent changes have optimized treatment decisions based on risk assessment, molecular profiling, and imaging assessment, leading the development of targeted agents that have modified the natural history of this disease. This increasing complexity on treatment options requires careful assessment at the different stages of the disease to provide the most suitable approach from diagnosis to long-term follow-up. This guideline aims to offer a comprehensive and practical overview on the current status and last updates of TC management.  \nKeywords Thyroid carcinoma; Molecular alterations; Multidisciplinary; Systemic treatment  \nIncidence and epidemiology  \nThyroid cancer (TC) accounts for 3% of global cancer incidence and is the most common endocrine malignancy. In 2022, 821.173 new cases were estimated worldwide, with differences by geographical area, age, and sex, although it only constitutes 0.5% of mortality, with an estimated number of 47.485 cases [1] .  \nFocusing on estimated data from Spain, European standardized incidence rates ofTC in 2020 are 16.2 cases/100 .000 inhabitants in women and 4.7 in men. Mortality rates are similar in both sexes, 0.7 cases/100 .000 inhabitants in women and 0.6 in men [2] . Estimated number of new thyroid cancer cases in Spain for 2023 was 6084 (Red Española de Registros de Cáncer) [3] .  \nUsing data from European cancer registries, in women, papillary thyroid carcinoma (PTC) constitutes 73% of all cases, follicular thyroid carcinoma (FTC) 14%, medullary thyroid carcinoma (MTC) 3%, anaplastic/undifferentiated carcinoma 3%, other histologies 2% and unspecified histology 4% . In men, this distribution accounts 64%, 16%, 7%, 4%, 3% and 6%, respectively [4] .  \nTeresa Alonso-Gordoa, Paula Jimenez-Fonseca, Javier MartinezTrufero, Miguel Navarro, Ignacio Porras, Jordi Rubió-Casadevall, Marta Arregui Valles, Neus Basté, Jorge Hernando and Lara Iglesias Docampo contributed equally to the manuscript.  \nExtended author information available on the last page of the article  \nA worldwide increase in the incidence of PTC in the last thirty years has been described. Implementation of cancer screening, better diagnostic accuracy and availability of neck ultrasound (US) or other imaging studies could be the reasons that explains this phenomenon. This leads to a growing diagnosis of clinically asymptomatic low-risk PTCs, which probably does not influence in patient’s survival. Differences in incidence between European countries are almost exclusively limited to PTC, which suggests that the patterns of overdiagnosis of this histology are probable culprits for this fact [4] .  \nThe only well-established risk factor for follicular cellderived TC is ionizing radiation, particularly exposure during childhood. Other factors (obesity, smoking, hormonal exposures, familial history, and certain environmental pollutants) may also contribute [5] . For MTC, the risk associated to germline RET mutations in the context of hereditary syndromes, such as MEN2 (Multiple Endocrine Neoplasia 2), is between 80 and 100% .  \nWhile most TC patients have an excellent prognosis, with a 5-year relative survival (5-y RS) rate of 98.2% for all stages; 99.9% in localized, and 98.2% for regional stages according to SEER data from the 2009–2015 cohort, the prognosis for distant disease drops to 56.2%[6]. According to histological subtype, TC patients diagnosed in E","cbCaioOzeaSkuTvh","https://ap.wps.com/l/cbCaioOzeaSkuTvh","pdf",2120743,15,"English","# Abstract\n# Incidence and epidemiology\n## Global burden and mortality\n## Spain estimates and mortality\n## Histological distribution by sex\n# Risk factors and prognosis\n## Risk factors by subtype\n## Survival by stage and histology\n# Methodology\n# Diagnosis, pathology, and molecular biology\n## Diagnostic workflow for suspicious thyroid nodules\n## Ultrasound risk stratification and FNAC indications\n## Bethesda classification scenarios","[{\"question\":\"What key factors are used to optimize thyroid cancer treatment decisions in recent practice?\",\"answer\":\"Treatment decisions are increasingly optimized using risk assessment, molecular profiling, and imaging assessment, which supports more tailored strategies and targeted agents.\"},{\"question\":\"How common is thyroid cancer and what is its mortality share?\",\"answer\":\"Thyroid cancer accounts for 3% of global cancer incidence and is the most common endocrine malignancy; it represents about 0.5% of mortality with an estimated number of cases reported in the article.\"},{\"question\":\"What is the standard diagnostic process for a patient with a suspicious thyroid nodule?\",\"answer\":\"The guideline describes blood tests for thyroid function, ultrasound scans, and fine-needle aspiration cytology (FNAC), with ultrasound features and risk levels guiding the need for FNAC.\"}]","SEOM‑GETNE‑TTCC Clinical guideline thyroid cancer (2023) | PDF",1790035045,38]